PTSD

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 20 weeks, CBTi+CPT produced significantly greater reductions in PTSD severity compared to Control+CPT. CAPS scores decreased by approximately 36 points in CBTi+CPT versus approximately 23 points in

Effect: improvement; ~36 point CAPS reduction (CBTi+CPT) vs ~23 point reduction (Control+CPT)

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51

At 6 weeks, participants receiving CBTi had significantly greater reductions in PTSD severity (CAPS) compared to attention control, with a moderate effect size (d = 0.51), comparable to the meta-analy

Effect: improvement; d = 0.51